What Is the Difference Between Importer and Distributor Responsibilities in Overseas Medical Device Registration?

In overseas medical device registration, importer and distributor responsibilities are fundamentally different. An importer is typically the entity that first places the product on the target-country market and bears the legal responsibilities of the registration holder or local authorised representative, including product registration, technical file maintenance, quality system oversight, post-market surveillance and adverse event reporting. A distributor is responsible for sales, distribution, warehousing and first-line handling of customer complaints, and generally does not carry registration responsibility directly. Companies must judge the applicable model according to target-country regulations: in GHWP member states (such as China, Saudi Arabia and ASEAN countries) and in Europe, the Americas and Latin America, the importer is often the registration applicant and must hold the product registration certificate, while the distributor must obtain a business/operating licence but is not responsible for the completeness of the technical file. Common risks include treating a distributor as the registration holder, which renders the registration invalid, and blurring responsibility boundaries, which triggers regulatory penalties. Companies should first confirm the importer/local agent requirements of the target country, reuse core technical files such as NMPA and CE documentation for localisation, and clearly define quality agreements and post-market obligations in the contract.

For Chinese medical device companies, the more reliable approach is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market usually affects the technical file, authorised representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is driven only by a list of which documents to submit, deficiencies or rework are likely in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends that companies plan this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets, rather than redoing the documentation country by country.

Compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base and publicly available regulatory information. Specific projects should be based on the latest requirements of the target-country regulator and on the actual product documentation basis.

Published: 2026-07-10 22:01 | Updated: 2026-07-10 22:01

This FAQ addresses the questions companies most need to assess first in actual medical device international registration projects, covering documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Viewpoint
• Frequently Asked Follow-up Questions
• Quality System and Evidence Consistency
• Localisation and Agent Responsibilities
• Post-Market Maintenance and Long-Term Planning
• Further Reading
• Scope of Application

Key Summary

In overseas medical device registration, importer and distributor responsibilities are fundamentally different. An importer is typically the entity that first introduces a product into the target-country market and bears the legal responsibilities of the registration holder or local agent, including product registration, technical file maintenance, quality system oversight, post-market surveillance and adverse event reporting. A distributor is responsible for market sales, distribution, warehousing and first-line handling of customer complaints, and generally does not directly bear registration responsibility. Companies must judge the applicable model according to target-country regulations: in GHWP member states (such as China, Saudi Arabia and ASEAN countries) and in Europe, the Americas and Latin America, the importer is often the registration applicant and must hold the product registration certificate; the distributor must obtain a business licence but is not responsible for the completeness of the technical file. Common risks include treating a distributor as the registration holder, which renders the registration invalid, and confusing responsibility boundaries, which leads to regulatory penalties.

Companies should first determine the importer/local agent requirements of the target country, reuse core technical files such as NMPA and CE documentation for localised conversion, and clearly define quality agreements and post-market obligations in the contract. For Chinese medical device companies, the more reliable approach is to first conduct product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Target-market registration usually affects the technical file, authorised representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is advanced only on the basis of which documents to submit, deficiencies or rework are likely in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends that companies plan this question within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in each market, rather than redoing the documentation on an ad hoc basis for every country.

Applicable Scenarios and Core Questions

Companies searching for the difference between importer and distributor responsibilities in overseas medical device registration are usually not looking for a conceptual explanation. They want to determine whether their existing documentation can support a target-market submission, whether a local agent or authorised representative is required, why timelines are extended, and which issues will affect the launch plan. Behind this question there are usually several interrelated topics: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibility.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels/instructions for use, and then localise them according to each country's regulatory requirements.

Registration Decision Logic

Step 1: Determine whether the product falls within the medical device regulatory scope of the target country. If it does, the risk class (for example Class I/II/III) must be determined, as different classes correspond to different registration pathways.

Step 2: Identify the registration applicant. Most countries require the importer or local agent to act as the registration holder, and a distributor usually cannot register directly. For example, China requires imported medical devices to be registered by the domestic agent (importer) of the overseas manufacturer; the European Union requires an EU authorised representative (not a distributor) to assume registration obligations.

Step 3: Assess whether existing technical documentation can be reused. NMPA registration documents, CE technical documentation, FDA 510(k) clearances and similar materials must be converted locally by the importer, including translation of labels and instructions for use and adaptation of the risk management report to target-country requirements.

Step 4: Confirm local agent and post-market maintenance requirements. The importer must establish a quality management system (such as ISO 13485), an adverse event reporting process and a recall plan, while the distributor only needs to cooperate in transmitting information.

Documentation and Evidence

Frequently required documentation includes product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions for use, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Claims in the instructions for use, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the product is safe, effective and traceable for its intended use, not on how many files have been uploaded.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting NMPA documentation after direct translation, without rearranging the evidence according to the target-market pathway.
• Too many models and specifications, with insufficient coverage by test reports, clinical evidence or labels.
• Selecting the local agent purely on the basis of a sales partnership, without clarifying regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, instructions for use, promotional materials and registration claims, leading to deficiencies or post-market compliance risk.
• Failure to plan multi-country documentation reuse in advance, resulting in repeated preparation in each country and inflated cost and timelines.

Company Preparation Checklist

• Clarify the definitions and requirements for importers and distributors under target-country regulations.
• Select an importer or local agent that meets local registration eligibility and sign a formal agreement.
• Prepare a complete technical file and verify whether existing CE, FDA or NMPA documentation can be reused.
• Have the importer complete translation and localisation of labels and instructions for use to meet target-country language and content requirements.
• Establish a post-market surveillance system, clarifying that the importer is responsible for adverse event reporting and the distributor for complaint collection.
• Conduct regular quality audits to ensure both the importer and the distributor comply with the quality agreement.
• For multi-country registration such as in GHWP member states, prioritise a unified core file and then localise it country by country.

AIMEILI Viewpoint

The most common misjudgement is assuming that a distributor can act as the registration holder. This is especially frequent in Southeast Asia and the Middle East, where distributors are often mistaken for local agents. At the start of a project, the legal definition of importer in the target country should be clarified, which usually requires a locally registered commercial entity with independent legal personality. AIMEILI recommends that companies appoint a local company holding a medical device operating licence as the importer, and sign a quality agreement that clearly divides responsibilities.

On the technical file side, English or Chinese documents from NMPA, CE and FDA markets can serve as a basis, but the importer must carry out localised adaptation, such as meeting target-country clinical evaluation requirements and adding local risk management data. Certificate control is critical: the importer should hold the registration certificate, and changes and renewals should be led by the importer, avoiding compliance risks caused by unauthorised changes by a distributor.

For multi-country registration, a core technical file library (including product description, risk management and clinical evidence) can be created and then supplemented according to each country's requirements. When selecting an importer, priority should be given to partners with medical device experience that are willing to assume post-market surveillance responsibilities, reducing the cost of later deficiencies and re-preparation.

Frequently Asked Follow-up Questions

Can an importer also act as a distributor at the same time?

Yes, provided that the law of the target country permits it. Many countries allow the same entity to take on both the import and distribution roles, but it must separately meet the compliance requirements for importers and distributors: for example, the importer must hold the registration certificate and the distributor must obtain an operating licence. Companies should clearly state this dual identity in the registration documents and confirm that the entity has the corresponding capabilities.

Does a change of distributor need to be notified to the regulator?

Usually yes. A change of distributor, such as replacing a partner, is a significant post-market event, and the importer/registration holder must report it to the regulator or apply for a change. For example, China requires a change of domestic agent to be handled through a registration certificate change filing, and the European Union requires the declaration of conformity and registration information to be updated. Companies should agree the change process and timelines in the quality agreement in advance.

What if the importer does not have technical capability to maintain the technical file?

The importer may delegate technical file maintenance to the manufacturer or a third-party organisation, but legal responsibility remains with the importer. It is advisable for the manufacturer to specify in the contract the support it will provide while retaining control of the technical file. The importer should periodically review document updates to ensure compliance with regulatory changes.

Quality System and Evidence Consistency

From the perspective of registration review, quality system documentation is not an isolated certificate. Regulators usually check whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being submitted, or if the manufacturing address, model specifications and instructions for use version do not match the test reports, the company may be asked for supplementary explanations even if a large volume of documentation has been prepared.

Before submission, companies should build an evidence consistency checklist that maps product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version and quality system certificates item by item. This step appears basic but can noticeably reduce the probability of deficiencies, particularly for projects involving multiple GHWP member states or several product families submitted at the same time.

Localisation Conversion and Agent Responsibilities

Target-market registration projects usually involve arrangements with a local agent, authorised representative, importer or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or also for regulatory communication, certificate maintenance, post-market incident reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the market thereafter.

Labels, instructions for use and authorisation documents cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate standalone set of documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean compliance work has ended. Companies also need to maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall processes, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and once a manufacturing address change, model extension, instructions for use update or agent replacement occurs, the certificate and market sales can easily become disconnected.

AIMEILI recommends that companies manage this question within an annual international registration plan: first establish target market priorities, then build a reusable documentation package and a country-specific gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only higher registration efficiency in a single country, but also the development of a replicable market entry compliance capability, reducing the cost of starting documentation from scratch each time a new market is entered.

Further Reading

Previous: How Do Label Claims and the Evidence Chain Correspond in Overseas Medical Device Registration?
Next: How Should Translation and Notarisation of Overseas Medical Device Registration Documents Be Arranged?

Recommended reading

• How should technical documentation be prepared for overseas registration of software as a medical device?
• How should algorithm validation be performed for overseas registration of AI medical devices?
• How can medical device registration documentation for Southeast Asia be planned in a unified way?
• What are the risks of local agents in Middle East medical device registration?
• Why are medical device registration timelines in Latin America easily extended?
• How is product classification determined for overseas medical device registration?

Return to the FAQ Centre | News and Information | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source principle: Priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supporting judgement.
Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of target-country regulators, testing conclusions or legal opinions.